Author | Saraiva, Roberto M. | |
Author | Waghabi, Mariana C. | |
Author | Vilela, Maíra F. | |
Author | Madeira, Fabiana S. | |
Author | Silva, Gilberto M. Sperandio da | |
Author | Xavier, Sérgio S. | |
Author | Feige, Jean J. | |
Author | Hasslocher-Moreno, Alejandro Marcel | |
Author | Araujo-Jorge, Tania C. | |
Access date | 2016-01-28T12:41:35Z | |
Available date | 2016-01-28T12:41:35Z | |
Document date | 2013 | |
Citation | SARAIVA, Roberto M. et al. Predictive value of transforming growth factor-β1 in Chagas disease: towards a biomarker surrogate of clinical outcome. Royal Society of Tropical Medicine and Hygiene Transactions, v. 107, p. 518-525, 2013. | pt_BR |
ISSN | 0035-9203 | |
URI | https://www.arca.fiocruz.br/handle/icict/12641 | |
Language | eng | pt_BR |
Publisher | Oxford University Press | pt_BR |
Rights | restricted access | |
Title | Predictive value of transforming growth factor-β1 in Chagas disease: towards a biomarker surrogate of clinical outcome | pt_BR |
Type | Article | |
DOI | 10.1093/trstmh/trt050 | |
Abstract | Background: Transforming growth factor-b1 (TGF-β1) may be implicated in the development of Chagas heart disease. However, the clinical value of TGF-β1 measurement is yet to be determined. Methods: We retrospectively analyzed the outcome of 54 Chagas disease patients without heart failure and with left ventricular (LV) ejection fraction .45% whose TGF-β1 serum values were determined between January 1998 and December 1999. Primary end point was all-cause mortality and secondary end point was the combination of all-cause mortality or hospitalization due to worsening heart failure or cardiac arrhythmias. Results: TGF-β1 was independently associated with the occurrence of the primary and secondary end points. The optimal cutoff for TGF-β1 to identify the primary end point was 12.9 ng/ml (area under the curve = 0.82, p = 0.004, sensitivity 100%, and specificity 57%) and to identify the secondary end point was 30.8 ng/ml (area under the curve = 0.72, p = 0.03, sensitivity 60%, and specificity 86%). LV ejection fraction and LV end-diastolic diameter were also independent predictors of the primary and secondary endpoints, respectively. Conclusion: The described association between TGF-β1 and clinical outcome provides evidence towards the clinical value of TGF-β1 in Chagas disease. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Institut National de la Santé et de la Recherché Médicale. Grenoble, France. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Chagas disease | pt_BR |
Subject | Heart failure | pt_BR |
Subject | Transforming growth factor-b1 | pt_BR |
Subject | Echocardiography | pt_BR |
Subject | Prognosis | pt_BR |
DeCS | Doença de Chagas | pt_BR |
DeCS | Insuficiência Cardíaca | pt_BR |
DeCS | Ecocardiografia | pt_BR |
DeCS | Prognóstico | pt_BR |
e-ISSN | 1878-3503 | |